Journal
FRONTIERS IN PHYSIOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphys.2022.825992
Keywords
exercise; cardiovascular health; aCGRP; myokines; migraine
Categories
Funding
- Swiss National Science Foundation [160104]
- Novartis Stiftung fuer BiologischMedizinische Forschung [16A012]
Ask authors/readers for more resources
Regular physical activity has cardiovascular protective effects and increases the concentration of alpha-calcitonin gene-related peptide (alpha CGRP). Alpha CGRP plays a role in vasodilation and migraine. Mouse models suggest that loss of alpha CGRP disrupts the cardiovascular system's adaptation to exercise and worsens cardiovascular damage in chronic hypertension, which can be reversed by alpha CGRP administration. This suggests that alpha CGRP agonists may be a therapeutic option for cardiovascular protection when exercise is not possible or contraindicated. However, the long-term cardiovascular safety of anti-CGRP therapy in individuals with cardiovascular diseases is still uncertain.
Regular physical activity exerts cardiovascular protective effects in healthy individuals and those with chronic cardiovascular diseases. Exercise is accompanied by an increased plasma concentration of alpha-calcitonin gene-related peptide (alpha CGRP), a 37-amino acid peptide with vasodilatory effects and causative roles in migraine. Moreover, mouse models revealed that loss of alpha CGRP disrupts physiological adaptation of the cardiovascular system to exercise in normotension and aggravates cardiovascular impairment in primary chronic hypertension, both can be reversed by alpha CGRP administration. This suggests that alpha CGRP agonists could be a therapeutic option to mediate the cardiovascular protective effects of exercise in clinical setting where exercise is not possible or contraindicated. Of note, FDA has recently approved alpha CGRP antagonists for migraine prophylaxis therapy, however, the cardiovascular safety of long-term anti-CGRP therapy in individuals with cardiovascular diseases has yet to be established. Current evidence from preclinical models suggests that chronic alpha CGRP antagonism may abolish the cardiovascular protective effects of exercise in both normotension and chronic hypertension.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available